Literature DB >> 33735492

Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.

Dan Bai1,2, Huhu Feng1, Jiajun Yang1, Aiping Yin3, Airong Qian4,5,6, Hiroshi Sugiyama7,8.   

Abstract

The tumor microenvironment, comprised of tumor cells and tumor-infiltrating immune cells, is closely associated with the clinical outcome of clear cell renal cell carcinoma (ccRCC) patients. However, the landscape of immune infiltration in ccRCC has not been fully elucidated. Herein, we applied multiple computational methods and various datasets to reveal the immune infiltrative landscape of ccRCC patients. The tumor immune infiltration (TII) levels of 525 ccRCC patients using a single-sample gene were examined and further categorized into immune infiltration subgroups. The TII score was characterized by distinct clinical traits and showed a significant divergence based on gender, grade, and stage. A high TII score was associated with the ERBB signaling pathway, the TGF-β signaling pathway, and the MTOR signaling pathway, as well as a better prognosis. Furthermore, patients with high TII scores exhibited greater sensitivity to pazopanib. The low TII score was characterized by a high immune infiltration level of CD8+ T cells, T follicular helper cells, and regulatory T cells (Tregs). Moreover, the immune check point genes, including CTLA-4, LAG3, PD-1, and IDO1, presented a high expression level in the low TII score group. Patients in the high TII score group demonstrated significant therapeutic advantages and clinical benefits. The findings in this study have the potential to assist in the strategic design of immunotherapeutic treatments for ccRCC.
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  clear cell renal cell carcinoma; immune cell infiltration; immune check point; immunotherapy; tumor microenvironment

Year:  2021        PMID: 33735492     DOI: 10.1111/cas.14887

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Hepcidin as a prognostic biomarker in clear cell renal cell carcinoma.

Authors:  Zijian Zhou; Jiajin Wu; Yuanyuan Yang; Peng Gao; Lujia Wang; Zhong Wu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature.

Authors:  Wenwei Chen; Wenfeng Lin; Liang Wu; Abai Xu; Chunxiao Liu; Peng Huang
Journal:  Int J Med Sci       Date:  2022-01-24       Impact factor: 3.738

3.  A prognosis model for clear cell renal cell carcinoma based on four necroptosis-related genes.

Authors:  Qiangmin Qiu; Yanze Li; Ye Zhang; Yanguang Hou; Juncheng Hu; Lei Wang; Zhiyuan Chen; Yourong Lei; Yang Du; Xiuheng Liu
Journal:  Front Med (Lausanne)       Date:  2022-08-09

4.  Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma.

Authors:  Xuezhong Shi; Yali Niu; Yongli Yang; Nana Wang; Mengyang Yuan; Chaojun Yang; Ani Dong; Huili Zhu; Xiaocan Jia
Journal:  Oxid Med Cell Longev       Date:  2022-08-23       Impact factor: 7.310

5.  A novel necroptosis-related lncRNAs signature for survival prediction in clear cell renal cell carcinoma.

Authors:  Liwen Zhao; Huaijing Luo; Xingmo Dong; Zhihui Zeng; Jianlong Zhang; Yi Yi; Chaolu Lin
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

6.  A New Prognostic Risk Signature of Eight Ferroptosis-Related Genes in the Clear Cell Renal Cell Carcinoma.

Authors:  Ji Chen; Yating Zhan; Rongrong Zhang; Bo Chen; Junting Huang; Chunxue Li; Wenjie Zhang; Yajing Wang; Yuxiang Gao; Jianjian Zheng; Yeping Li
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.